Allogeneic NK cells combined with 2 weeks’ adjuvant IL-2 were administered in a phase II trial in 20 patients with solid tumors (14 ovarian, 6 breast cancer) following the low dose, non-myeloablative preparative regimen (230). This evidence concerns the gene IL2 and breast carcinoma.